?Effect of sofosbuvir/ ledipasvir on COVID-19
Phase 2
Recruiting
- Conditions
- COVID-19 pneumonia.
- Registration Number
- IRCT20100228003449N29
- Lead Sponsor
- Tehran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Patients with highly suspected diagnosis of COVID-19
Patients with confirmed diagnosis of COVID-19
Patients who are candid for hospitalization
Patients who are candid for starting triple-drug combination
Exclusion Criteria
History of drug allergy
Pregnancy
Lactation
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Response to the treatment (improvement of patients' chief complaint, abnormal paraclinic and radiologic findings). Timepoint: Daily. Method of measurement: According the clinical, paraclinical and laboratory findings.;Gastrointestinal complications. Timepoint: Daily. Method of measurement: Interview and patient's record.;Cutaneous complications. Timepoint: Daily. Method of measurement: Interview and patient's record.;Neurological complications. Timepoint: Daily. Method of measurement: Interview and patient's record.;Renal complications. Timepoint: Daily. Method of measurement: Interview and patient's record.;Hematological complications. Timepoint: Daily. Method of measurement: Interview and patient's record.
- Secondary Outcome Measures
Name Time Method Duration of hospitalization. Timepoint: End of the treatment. Method of measurement: Patient's record.;Clinical outcome (cure or death). Timepoint: End of treatment. Method of measurement: Patient's record.